Skip to main content

Table 20 Binding or neutralizing antibodies directed against anti-CGRP monoclonal antibodies in available randomized clinical trials

From: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Author, Year

Phase, setting

Participants (n)

Follow-up

Binding antibodies

Neutalizing antibodies

Clinical implications

Eptinezumab

 Dodick, 2014 [32]

II, EM

174

3 months

11/81

–

None

Erenumab

 Sun, 2016 [44]

II, EM

483

3 months

13/107 for 7 mg

12/102 for 21 mg

8/104 for 70 mg

5/107 for 7 mg

3/102 for 21 mg

1/104 for 70 mg

None

 Tepper, 2017 [45]

II, CM

667

3 months

11/190 for 70 mg

3/188 for 140 mg

0

None

 ARISE [36]

III, EM

955

6 months

8.0% for 70 mg

3.2% for 140 mg

0.2% for 70 mg

0 for 140 mg

None

 STRIVE [34]

III, EM

577

3 months

4.3% for 70 mg

0.3% for 70 mg*

None

Fremanezumab

 Bigal, 2015 [27]

IIb, EM

297

3 months

1%§

–

None

 Bigal, 2015 [26]

IIb, CM

264

3 months

1%§

–

None

 HALO EM [34]

III, EM

875

3 months

1.4% for the monthly dosing

0 for single high dose

–

None

 HALO CM [41]

III, CM

1130

3 months

1%

–

None

Galcanezumab

 REGAIN [31]

III, CM

836

3 months

2.7% for 120 mg

2.6% for 240 mg

2.3% for 120 mg

1.5% for 240 mg

None

 Dodick, 2014 [33]

II, EM

218

3 months

15.7%#

 

None

 EVOLVE 2 [42]

IIb, EM

936

3 months

–

–

None

 EVOLVE 1 [43]

III, EM

1671

6 months

3.5% for 120 mg¶

5.2% for 240 mg¶

0.2%

None

  1. *positive at week 4 for but negative at each subsequent visit; §patients were positive at baseline; #including 6.2% of patients who were positive at baseline; ¶only treatment emergent antibodies